

Synthesis of Glycopolymers Carrying 3' - Sialyllactose for Suppressing Inflammatory Reaction via Siglec-E

Ishida, Takato

Department of Chemical Engineering, Kyushu University

Nagao, Masanori

Department of Chemical Engineering, Kyushu University

Oh, Takahiro

Department of Chemical Engineering, Kyushu University

Mori, Takeshi

Department of Applied Chemistry, Kyushu University

他

<https://hdl.handle.net/2324/4793646>

出版情報 : Chemistry Letters. 51 (3), pp.308-311, 2022-01-21. The Chemistry Society of Japan
バージョン :
権利関係 :



Synthesis of Glycopolymers Carrying 3'-Sialyllactose for Suppressing Inflammatory Reaction *via* Siglec-E

Takato Ishida,¹ Masanori Nagao,¹ Takahiro Oh,¹ Takeshi Mori,² Yu Hoshino,¹ and Yoshiko Miura*¹
¹Department of Chemical Engineering, Kyushu University, 744, Motoooka, Nishi-ku, Fukuoka 819-0395
²Department of Applied Chemistry, Kyushu University, 744, Motoooka, Nishi-ku, Fukuoka 819-0395

E-mail: miuray@chem-eng.kyushu-u.ac.jp

One of the new strategies to treat autoimmune diseases is to target Siglec, a membrane protein receptor with the ability to suppress immune responses. Herein, we synthesized glycopolymers carrying 3'-sialyllactose in various glyco unit densities. RAW 264.7 macrophages transfected to express secreted alkaline phosphatase (SEAP) were used to evaluate the immunosuppression ability of the glycopolymers. The inhibition of the signal transmission was dependent on the glyco unit densities of the glycopolymers, and was maximized at the moderate density (70%).

Keywords: Glycopolymers, Siglec, RAFT polymerization

Immunity is a biological response that eliminates antigens such as bacteria, viruses, and other pathogens, and plays an important role in biological activities.¹ In some cases, malfunctions of the immune systems cause autoimmune diseases where immune cells attack their own cells and tissues, resulting in inflammation.^{2,3} To date, drugs targeting immune cells and inflammatory cytokines have been developed; however, there are various side effects (e.g., inhibition of normal cell proliferation, morbidity from other infections due to reduced inflammatory cytokines), and thus, the development of novel drugs that exhibit immunosuppression through another mechanism has been required.^{4,5}

Sialic acid-binding immunoglobulin-like lectins (Siglec) are a family of immune checkpoint receptors expressed on cells of the immune and hematopoietic systems, and are emerging as targets for new immune response modulators.⁶⁻⁹ Each of Siglec types recognizes the corresponding sialic acid residue as ligands, and plays roles as a regulator of immune cell signaling.^{6,10-12} Siglec-9 has an immunoreceptor tyrosine-based inhibitory motif (ITIM) near the plasma membrane that transmits inhibitory functions to immune cells, and has been reported to suppress the production of the pro-inflammatory cytokines TNF- α and IL-6, and to increase the production of the inhibitory cytokine IL-10.¹³⁻¹⁵ The Siglec molecules are usually masked by glycoconjugates on the cell surface, and therefore, dissociation of the binding of sialic acid, a natural ligand for Siglec (K_d = mM), by competitive ligands is required to control the transmit immunosuppressive signals.^{6,16,17}

Glycoproteins that strongly interact with Siglec have been developed as the competitive ligands.¹⁸⁻²² Since the accumulation of Siglecs on membranes is also thought to trigger signal transduction, polymeric molecules with multiple carbohydrates that can cross-link multiple Siglec molecules are attracting attention.^{6,23,24} Glycopolymers are a class of polymeric glycoligands, and have advantages of easy




Figure 1. Schematic illustrations of the synthesis of glycopolymers carrying 3'-sialyllactose units.

synthesis.^{25,26} Glycopolymers have multiple glyco units in one molecule, and increase the probability of binding to a lectin resulting in the strong interaction (the cluster glycoside effect).^{27,28} Furthermore, the interaction of glycopolymers with target molecules can be controlled by designing the structures of the glycopolymers (polymer length and glyco density) using controlled polymerization.²⁹⁻³¹ Bertozzi et al. reported the interaction of the glycopolymers with Siglec-7 and -9.^{24,32} However, the effect of polymer structures on the interaction with Siglec-9 has not been studied in detail.


Herein, we synthesized glycopolymers carrying 3'-sialyllactose (3'-SALac) in different glyco unit densities for immunosuppression via interactions with Siglec-E, a true ortholog of Siglec-9. For effective introduction of the bulky trisaccharide into the polymer side chains, the glycopolymers were synthesized using "post-click" chemistry, which is a combination of controlled polymerization and "click" reaction.

Polymer precursors carrying protected alkyne groups were synthesized by reversible addition-fragmentation chain transfer (RAFT) polymerization with 3-(trimethylsilyl)prop-2-yn-1-yl acrylate (TMSPA) and tetrahydrofurfuryl acrylate (ThfAc). ThfAc was chosen as the amphiphilic spacer monomer. The monomers, the RAFT agent methyl 2-(((butylthio)carbonothioyl)-thio)propanoate (MCEBTTC), and the initiator 2,2'-azobis(isobutyronitrile) (AIBN) were

Table 1. Properties of RAFT polymerization of polymer precursors.

Polymers	Monomer feed ratio		Conv. ^a (%)	DP ^a		$M_{n,th}^b$ (g/mol)	M_n^c (g/mol)	M_w/M_n^c (-)
	TMSPA (mol%)	ThfAc (mol%)		TMSPA (mer)	ThfAc (mer)			
P1	10	90	98	8	91	15,900	13,600	1.53
P2	30	70	95	32	80	18,600	13,600	1.57
P3	50	50	91	42	47	15,200	14,000	1.69
P4	70	30	89	64	27	16,100	13,400	1.57
P5	90	10	89	76	13	16,100	11,300	1.53

Monomer concentration of each polymerization ([M]) was set at 5.0 M. The target degree of polymerization (DP) was set at 100 ([M]/[RAFT] = 100). The ratio of the initiator ([RAFT]/[AIBN]) was fixed at 50. (a) Monomer conversion (Conv.) and the degree of polymerization (DP) were determined from ¹H NMR. (b) Theoretical molecular weight was calculated by following the formula: $M_{n,th} = MW_{CTA} + MW_{TMSPA} \times DP_{TMSPA} + MW_{ThfAc} \times DP_{ThfAc}$ (c) Relative molecular weight and polydispersity index were determined by GPC analysis calibrated with a PMMA standard. The eluent was DMF with LiBr (10 mM).

**Figure 2.** GPC traces of (a) P1 to P5 (eluent; DMF with 10 mM LiBr, standard; PMMA), (b) G1 (eluent; DMF with 10 mM LiBr, standard; PMMA), and (c) G2 to G5 (eluent; 100 mM NaNO₃ (aq), standard; pullulan).

1 dissolved in toluene with a stoichiometry of [monomer]:
2 [RAFT]: [Initiator] = 100: 1: 0.2 ([monomer] = 5 M). The
3 ratio of [TMSPA]: [ThfAc] was varied from 1: 9 to 9: 1, and
4 poly(TMSPA-*r*-ThfAc) (P1 ~ P5) were obtained. Conversion
5 rate and the degree of polymerization (DP) were determined
6 by ¹H NMR. Molecular weight and polydispersity (M_w/M_n)
7 were confirmed by gel permeation chromatography (GPC)
8 analysis. The monomer conversions were over 89% and the
9 polydispersities were below 1.69 for all conditions (Table 1).
10 The DP values of each monomer in the obtained polymers
11 were TMSPA: ThfAc = 8: 91 (P1), 32: 80 (P2), 42: 47 (P3),
12 64: 27 (P4), and 76: 13 (P5), indicating that the synthesized
13 polymers had the designed monomer ratio. The GPC curves
14 of P1 and P5 showed the shoulders on the high-molecular side
15 and tailing on the low-molecular side, which were attributed
16 to the polymerization properties of ThfAc and TMSPA,
17 respectively (Figure 2a and S2). Although the dispersities
18 were relatively broad as RAFT polymers, the synthesized
19 polymer precursors carrying the protected alkyne groups in
20 different densities were obtained. Sequentially, the TMS
21 groups of the polymer precursors were deprotected using
22 tetrabutylammonium fluoride in dry THF at room
23 temperature. The complete deprotection of the TMS groups
24 were confirmed by ¹H NMR (Figure S1-13-1-17).

25 Neu5Ac- α (2-3)-Gal- β (1-4)-Glc (3'-SALac), which is
26 recognized by Siglec-E (-9), was selected as a carbohydrate
27 ligand to be introduced into the side chain.^{13,33-35} The
28 anomerically azidized 3'-SALac azide was introduced into
29 the side chain of P1-P5 by Huisgen reaction (G1-G5, Figure
30 1). The yield of the addition reaction and the number of the

31 glycount in the polymer molecule (glycount density) were
32 confirmed by ¹H NMR (400 MHz). In all conditions, the
33 yields of the glycount addition were over 89%, and glycount
34 densities were 7, 26, 45, 65, and 76% for G1-G5, respectively
35 (Table 2). It should be noted that an error of about 10% was
36 observed in the integral values for the proton peaks. GPC
37 analysis revealed the polydispersities were below 1.64,
38 demonstrating that the reaction proceeded without any
39 damage to the polymer main chains (Figure 2b and 2c). Thus,
40 the combination of RAFT polymerization and Huisgen
41 reaction enabled the synthesis of the glycopolymers carrying
42 bulky 3'-SALac in various glycount densities.

43 To evaluate the immunosuppression with synthesized
44 glycopolymers, SEAP Raw 264.7 macrophage-like cells that
45 express high levels of Siglec-E in response to LPS
46 stimulation were used.^{36,37} SEAP Raw 264.7 cells produce
47 secreted alkaline phosphatase (SEAP) via the NF- κ B
48 pathway through TLR4 signaling in response to LPS
49 stimulation.³⁸ Taking advantage of the fact that SEAP
50 hydrolyzes the phosphate group of *p*-nitrophenylphosphate
51 (pNPP) to produce a compound with an absorbance at 405
52 nm, the SEAP production was evaluated with enzyme-linked
53 immunosorbent assay (ELISA). The low glycount density of

Table 2. Properties of the glycopolymers synthesized by Huisgen reaction.

Polymers	Alkyne conv. ^a (%)	Glycount density ^a (%)	$M_{n,th}^b$ (g/mol)	$M_n^{c,d}$ (g/mol)	$M_w/M_n^{c,d}$ (-)
G1	>92	7	20,100	24,000	1.63
G2	>90	26	36,000	25,000	1.63
G3	>95	45	39,400	28,000	1.64
G4	>93	65	52,300	49,000	1.34
G5	>89	76	56,900	44,000	1.34

(a) Alkyne conversion and the glycount density were determined from ¹H NMR. (b) Theoretical molecular weight was calculated by following the formula: $M_{n,th} = MW_{CTA} + MW_{(PA+3'-SALac)} \times DP_{(PA+3'-SALac)} + MW_{(PA)} \times DP_{PA} + MW_{ThfAc} \times DP_{ThfAc}$ (c) Relative molecular weight and polydispersity index of G1 were determined by GPC analysis calibrated with PMMA standard. The eluent was DMF with 10 mM LiBr. (d) Relative molecular weight and polydispersity index of G2 to G5 were determined by GPC analysis calibrated with a Pullulan standard. The eluent was 100 mM NaNO₃ (aq).




Figure 3. Suppression of LPS-induced SEAP production in RAW 264.7 macrophage-like cells by glycopolymers. Cells were incubated overnight and then treated with (a), (b), (c), and (d) glycopolymers (0.5, 0.1, 0.05, 0.01 mM) and (e) 3'-SALac (50 mM) for 30 min. After 30 min later, the cells were stimulated LPS (final conc. 100 ng/mL) for 24 h. The absorbance at 405 nm of the supernatants was then measured by ELIZA. The horizontal axis of (e) shows the concentration of 3'-SALac (mM), and the subscript of number means materials (G3, G4 and G5 are at 0.5 mM, G4* is at 0.1 mM of the polymer concentration). The sialic acid concentration of glycopolymers was calculated by following the formula: Sialic acid concentration = polymer concentration \times DP_(PA+3'SALac). In all graphs, "Ref" means without sugars and glycopolymers; that is 0 mM. All assays were performed in triplicate, and data are expressed as means \pm 2*SD. ****, p < 0.0005 (two-sided); significantly different from the group treated with LPS alone by Student's t test

1 G1 (8%) resulted in its low solubility in buffer solution (PBS),
 2 and thus, G1 was not used in this assay. G2–G5 were
 3 dissolved in a mixture of solvents (DPBS (Ca(-), Mg(-) and
 4 medium) to final concentrations (0.5, 0.1, 0.05, 0.01 mM) to
 5 prepare glycopolymer solutions. As compared to the
 6 reference well (without glycopolymers), the wells treated
 7 with G3, G4 and G5 at high polymer concentration (0.5 mM)
 8 showed significant decrease in the absorbance at 405 nm
 9 (Figure 3b-d, p < 0.0005). The decrease in absorbance was
 10 90, 85 and 99% for G3, G4 and G5, respectively. Furthermore,
 11 only G4 showed the decrease in absorbance at lower polymer
 12 concentration (0.1 mM, 60% decrease). There was no
 13 significant difference in the absorbance of G2 and 3'-SALac
 14 monomer (Figure 3a and e).

15 These results indicate that SEAP production was
 16 inhibited by glycopolymers with the glyconut density of
 17 48% or higher, suggesting interactions of the glycopolymers
 18 with Siglec-E on the cell surface. Since 3'-SALac monomer
 19 and G2 (low glyconut density) did not show any suppression,
 20 a certain glyconut density was necessary for the expression
 21 of the suppressive ability. We presume that the high glyconut
 22 densities of G3–G5 (>48%) increased the binding probability
 23 of 3'-SALac to Siglec-E, resulting in the lower k_{off} . In
 24 addition, G4, with 70% glyconut density, showed inhibition
 25 of SEAP production at the lowest polymer concentration.
 26 This suggests that there is an optimal glyconut density or
 27 polymer conformation where the steric hindrance of the
 28 trisaccharide structure is avoided in binding to Siglec-E.³⁰

29 In conclusion, we synthesized glycopolymers carrying
 30 3'-SALac, which interacts with Siglec-E, using the
 31 combination of RAFT polymerization and Huisgen reaction.

32 Then, the glyconut densities were varied from 7 to 76%.
 33 Evaluation of immunosuppression of the glycopolymers
 34 indicated that signal transduction via the NF- κ B pathway was
 35 inhibited, and that the inhibition ability was dependent on the
 36 glyconut density. This signal suppression was achieved by
 37 the multivalency of the glycopolymers, and the moderate
 38 glyconut density maximized the ability. These results
 39 demonstrate the successful development of the polymeric
 40 glycoligand that targets Siglec-E, resulting in
 41 immunosuppression. In the future, we expect to develop
 42 materials with higher inhibitory ability by further design of
 43 polymer structures.

45 Acknowledgement

46 This work was supported by a JSPS KAKENHI Grant
 47 Number JP20H05230, JP20H04825, and JP19H02766.
 48 We also thank for the great help from Mr. Hiroki Takeuchi,
 49 Mr. Yunosuke Oshiro, Mr. Kazuki Nobuhiro, and Dr.
 50 Hirohiko Ise (Kyusyu University).

51
 52 Supporting Information is available on
 53 http://dx.doi.org/10.1246/cl.*****.

54 References

- 55 1 R. Medzhitov, *Nature*, **2007**, 449, 819.
- 56 2 L. Wang, F. S. Wang, M. E. Gershwin, *J. Intern. Med.*, **2015**, 278,
 57 369.
- 58 3 K. C. Navegantes, R. S. Gomes, P. A. T. Pereira, P. G. Czaikoski,
 59 C. H. M. Azevedo, M. C. Monteiro, *J. Transl. Med.*, **2017**, 15, 1.
- 60 4 T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L.
 61 Matteson, V. Montori, *Jama*, **2006**, 295, 2275.

- 5 M. Yasunaga, *Semin. Cancer Biol.*, **2020**, *64*, 1.
- 6 P. R. Crocker, J. C. Paulson, A. Varki, *Nat. Rev. Immunol.*, **2007**,
7, 255.
- 7 A. Varki, T. Angata, *Glycobiology*, **2006**, *16*, 1R.
- 8 G. Murugesan, B. Weigle, P. R. Crocker, *Curr. Opin. Chem. Biol.*,
2021, *62*, 34.
- 9 A. Bärenwaldt, H. Läubli, *Expert Opin. Ther. Targets*, **2019**, *23*,
839.
- 10 M. S. Macauley, P. R. Crocker, J. C. Paulson, *Nat. Rev. Immunol.*,
2014, *14*, 653.
- 11 J. C. Paulson, M. S. Macauley, N. Kawasaki, *Ann N Y Acad Sci.*,
2012, *1253*, 37.
- 12 S. J. McMillan, R. S. Sharma, E. J. McKenzie, H. E. Richards, J.
13 Zhang, A. Prescott, P. R. Crocker, *Blood*, **2013**, *121*, 2084.
- 14 T. Angata, A. Varki, *J. Biol. Chem.*, **2000**, *275*, 22127.
- 15 J. Q. Zhang, G. Nicoll, C. Jones, P. R. Crocker, *J. Biol. Chem.*,
2000, *275*, 22121.
- 16 M. Ando, W. Tu, K. Nishijima, S. Iijima, *Biochem. Biophys. Res.*
17 *Commun.*, **2008**, *369*, 878.
- 18 S. Duan, J. C. Paulson, *Annu. Rev. Immunol.*, **2020**, *38*, 365.
- 19 N. Razi, A. Varki, *Proc. Natl. Acad. Sci. U. S. A.*, **1998**, *95*, 7469.
- 20 L. D. Movsisyan, M. S. Macauley, *Org. Biomol. Chem.*, **2020**, *18*,
21 5784.
- 22 C. Büll, T. Heise, G. J. Adema, T. J. Boltje, *Trends Biochem. Sci.*,
2016, *41*, 519.
- 23 J. G. Briard, H. Jiang, K. W. Moremen, M. S. Macauley, P. Wu,
24 *Nat. Commun.*, **2018**, *9*, 880.
- 25 C. D. Rillahan, E. Schwartz, R. McBride, V. V. Fokin, J. C.
26 Paulson, *Angew. Chem. Int. Ed.*, **2012**, *51*, 11014.
- 27 S. Yamaguchi, A. Yoshimura, Y. Yasuda, A. Mori, H. Tanaka, T.
28 Takahashi, K. Kitajima, C. Sato, *Chem. Bio. Chem.*, **2017**, *18*,
29 1194.
- 30 C. S. Delaveris, S. H. Chiu, N. M. Riley, C. R. Bertozzi, *Proc. Natl.*
31 *Acad. Sci. U. S. A.*, **2021**, *118*, e2012408118.
- 32 A. Lizcano, I. Secundino, S. Döhrmann, R. Corriden, C. Rohena,
33 Diaz, P. Ghosh, L. Deng, V. Nizet, A. Varki, *Blood*, **2017**, *129*,
34 3100.
- 35 Y. Miura, Y. Hoshino, H. Seto, H., *Chem. Rev.*, **2016**, *116*, 1673.
- 36 L. L. Kiessling, J. C. Grim, *Chem. Soc. Rev.*, **2013**, *42*, 4476.
- 37 J. J. Lundquist, E. J. Toone, *Chem. Rev.*, **2002**, *102*, 555.
- 38 S. Cecioni, A. Imberty, S. Vidal, *Chem. Rev.*, **2015**, *115*, 525.
- 39 J. E. Gestwicki, C. W. Cairo, L. E. Strong, K. A. Oetjen, L. L.
40 Kiessling, *J. Am. Chem. Soc.*, **2002**, *124*, 14922.
- 41 Q. Zhang, J. Collins, A. Anastasaki, R. Wallis, D. A. Mitchell, C.
42 R. Becer, D. M. Haddleton, *Angew. Chem. Int. Ed.*, **2013**, *52*, 4435.
- 43 M. Nagao, Y. Fujiwara, T. Matsubara, Y. Hoshino, T. Sato, Y.
44 Miura, *Biomacromolecules*, **2017**, *18*, 4385.
- 45 J. E. Hudak, S. M. Canham, C. R. Bertozzi, *Nat. Chem. Biol.*, **2014**,
46 *10*, 69.
- 47 O. Blixt, B. E. Collins, E.; I. M. Nieuwenhof, P. R. Crocker, J. C.
48 Paulson, *J. Biol. Chem.*, **2003**, *278*, 31007.
- 49 A. F. Carlin, S. Uchiyama, Y. C. Chang, A. L. Lewis, V. Nizet, A.
50 Varki, *Blood*, **2009**, *113*, 3333.
- 51 P. Redelinghuys, A. Antonopoulos, Y. Liu, M. A. Campanero-
52 Rhodes, E. McKenzie, S. M. Haslam, A. Dell, T. Feizi, P. R.
53 Crocker, *J. Biol. Chem.*, **2011**, *286*, 34522.
- 54 C. R. Boyd, S. J. Orr, S. Spence, J. F. Burrows, J. Elliott, H. P.
55 Carroll, K. Brennan, J. N. Gabhann, W. A. Coulter, J. A. Johnston,
56 C. A. Jefferies, *J. Immunol.*, **2009**, *183*, 7703.
- 57 H. Liu, Y. Zheng, Y. Zhang, J. Li, S. M. Fernandes, D. Zeng, X.
58 Li, R. L. Schnaar, Y. Jia, *Biomed. Pharmacother.*, **2020**, *122*,
59 109760.
- 60 Y. Li, X. Wang, J. Ren, X. Lan, J. Li, J. Yi, L. Liu, Y. Han, S.
61 Zhang, D. Li, S. Lu, *BMC Pharmacol. Toxicol.*, **2017**, *18*, 5.

NOTE The diagram is acceptable in a colored form. Publication of the colored G.A. is free of charge.

For publication, electronic data of the colored G.A. should be submitted. Preferred data format is EPS, PS, CDX, PPT, and TIFF.

If the data of your G.A. is "bit-mapped image" data (not "vector data"), note that its print-resolution should be 300 dpi.

You are requested to put a brief abstract (50-60 words, one paragraph style) with the graphical abstract you provided, so that readers can easily understand what the graphic shows.

